Tempo-iMG™
Human iPSC-derived Microglia
Tempo-iMG™
Human iPSC-derived Microglia
Tempo-iMG™ microglia cells are reprogrammed from human iPSC-derived multipotent progenitor cells, using integration-free induced pluripotent stem cell (iPSC) lines under fully defined proprietary feeder-free, serum-free, non-viral, nucleic-acids-free, integration-free reprogramming conditions. Tempo’s iMG™ microglia cells are polarized structures when plated as a monolayer in culture and express microglia biomarkers, such as ApoE/variants, A1F1(= IBA1), hP2RY-12, TREM2, hGPR34, CXCR3, P2RX4, P2RX7, TRPM7, and CD11b/c. They exhibit phagocytosis activities (shown via LIVE-cell phagocytosis assay using fluorescent beads). Microglia are different from macrophages in many significant ways: synaptic stripping, secreting cytotoxic molecules, removing waste molecules from neurons, and signaling robust calcium wave responses.
Applications
Tempo-iMG™ are intended for basic scientific research, drug discovery and therapeutics development use only. It is not a product for human testing or diagnostics.
Disease modeling
Cytotoxicity evaluations
Phenotypic Screening (e.g., synaptic release assays, inflammatory cytokines ELISA assays)
Preclinical validation studies
In vitro assays using microglial cells
Tempo’s “Build an organoid” is easy to scale!
Ready in DAYS NOT WEEKS, and simplifies assay and data analysis.
iOligo, iMG

ratio to 6:1, 3:1, 4:1
Specifications
~1.0×10^6 cells per 1ml of freezing medium (vial)
Long-term Storage: liquid nitrogen
Growth Properties: adherent
Storage: remove cryovials (dry ice packaging) and place the vial into liquid nitrogen for storage. Alternatively, thaw and use the cells immediately.
Technology used: an in-house developed proprietary feeder-free, serum-free, non-viral, nucleic-acids-free, integration-free reprogramming technology.
QC: Sterility, Safety (BioSafety Level 2), HIV/viruses, bacteria, fungi: negative. Cell viability post-thawing (>90%)
Tempo-iMG™ SKU1001.1
Citations
- Human Cortex Spheroid with a Functional Blood Brain Barrier for High-Throughput Neurotoxicity Screening and Disease Modeling
- Cell Sources and Methods for Producing Organotypic in vitro Human Tissue Models
- Probing Prodrug Metabolism and Reciprocal Toxicity with an Integrated and Humanized Multi-Tissue Organ-on-a-Chip Platform
- Cross-talk between microglia and neurons regulates HIV latency
- Multicellular 3D Neurovascular Unit Model for Assessing Hypoxia and Neuroinflammation Induced Blood-Brain Barrier Dysfunction
- Transport of ultrasmall gold nanoparticles (2 nm) across the blood–brain barrier in a six-cell brain spheroid model